z-logo
open-access-imgOpen Access
Beneficial Effect of a Novel Diuretic, Ml7055, on Blood Pressure and Cardiovascular Hypertrophy in Spontaneously Hypertensive Rats
Author(s) -
Tomoaki Shinkawa,
Yasuhiro Kato,
Naho Tsuchiya,
Fumiaki Yamasaki,
Akinori Uemura,
Masahiro Mizota
Publication year - 1993
Publication title -
japanese journal of pharmacology/japanese journal of pharmacology
Language(s) - English
Resource type - Journals
eISSN - 1347-3506
pISSN - 0021-5198
DOI - 10.1254/jjp.63.241
Subject(s) - captopril , medicine , blood pressure , diuretic , muscle hypertrophy , endocrinology , aorta , ventricle , mesenteric arteries , thoracic aorta , artery
We investigated the effects of a novel diuretic, M17055, on blood pressure and cardiovascular hypertrophy in spontaneously hypertensive rats (SHR). M17055 was orally administered once a day for 24 consecutive days to 14-week-old male SHR. M17055 at doses of 1.25, 2.5 and 5 mg/kg/day exerted a dose-related diuretic and antihypertensive effect during the treatment. The weight of the left ventricle normalized by body weight on the following day of the last dosage was significantly (P < 0.01) reduced by M17055 at doses of 2.5 and 5 mg/kg/day in a dose-dependent manner. The effect of M17055 on cardiac hypertrophy was more potent (P < 0.01) than that of captopril, when the comparison was performed at the doses of M17055 and captopril inducing the same extent of blood-pressure decrement. Vascular hypertrophy was evaluated by the media/lumen ratio (M/L) in the thoracic aorta and the first branch of the superior mesenteric artery. In the aorta, M/L was slightly, but not significantly, decreased by M17055 at doses of 2.5 and 5 mg/kg/day, whereas it was decreased significantly (P < 0.01) by captopril. In the mesenteric artery, the ratio was significantly (P < 0.05) reduced by M17055 at a dose of 5 mg/kg/day. These results suggest that M17055 possesses beneficial properties for the clinical treatment of hypertension.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here